Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 11849.145 | 0.9602 | 0.9474 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 11849.145 | 0.9657 | 0.9548 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 11849.145 | 0.9904 | 0.9874 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 11849.145 | 1.0024 | 1.0032 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 11849.145 | 0.9153 | 0.8872 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 11849.145 | 1.0364 | 1.0475 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 11849.145 | 0.8601 | 0.8118 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 11849.145 | 1.0520 | 1.0676 | 1.5253 | |
| HCC1937 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 11849.145 | 1.1396 | 1.1789 | 1.5253 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 11055.145 | 1.0243 | 1.0274 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 11055.145 | 1.0559 | 1.0627 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 11055.145 | 1.0022 | 1.0025 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 11055.145 | 1.0465 | 1.0523 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 11055.145 | 1.0089 | 1.0101 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 11055.145 | 1.0341 | 1.0384 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 11055.145 | 1.0015 | 1.0017 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 11055.145 | 1.0451 | 1.0508 | 1.7616 | |
| HCC1954 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 11055.145 | 0.9817 | 0.9791 | 1.7616 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10996.145 | 0.9489 | 0.8259 | 0.5765 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10996.145 | 1.0139 | 1.0484 | 0.5765 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10996.145 | 1.0255 | 1.0894 | 0.5765 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10996.145 | 1.0321 | 1.1128 | 0.5765 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10996.145 | 0.9327 | 0.7722 | 0.5765 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10996.145 | 0.9951 | 0.9831 | 0.5765 | |
| HCC2185 | TNBC | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10996.145 | 0.9046 | 0.6808 | 0.5765 |